During maintenance treatment, the incidence of grade 3/ 4 cardiac disorders was comparable between patients treated with MabThera and observation.
Säilitusravi ajal oli 3. / 4. raskusastme südame häirete esinemissagedus võrreldav MabThera ja vaatlusrühma patsientidel.